Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*)

Next Previous
Trial Profile

Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Dec 2018

At a glance

  • Drugs Ivacaftor/lumacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Acronyms ORKAMBI

    • Most Recent Events

    • 18 May 2018 Planned End Date changed from 15 Jan 2020 to 30 Jun 2018.
    • 18 May 2018 Planned primary completion date changed from 30 Dec 2018 to 30 Jun 2018.
    • 18 May 2018 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top